ArriVent appoints Merdad Parsey to board; Carl Gordon not standing for re-election

ArriVent BioPharma, Inc.

Carl L. Gordon not standing for re-election at 2025 annual meeting (June 18); no disagreement with company.
Board expanded from 7 to 8; Merdad Parsey (former Gilead EVP/CMO) appointed effective April 28, 2025.
Parsey receives initial option grant of $352,000 and annual cash retainer of $45,000 plus $7,500 for committee service.
Directors Zhengbin Yao and Kristine Peterson reclassified from Class III to Class I to balance board classes.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Merdad Parsey

Director

AVBP · ArriVent BioPharma, Inc.

Effective: 2025-04-28
Filed: April 28, 2025, 7:59 PM ET

the Board approved, effective April 28, 2025, an increase in the size of the Board from seven (7) directors to eight (8) directors and appointed Merdad Parsey, M.D., Ph.D. to fill the newly created vacancy on the Board

Departed

Carl L. Gordon

Director

AVBP · ArriVent BioPharma, Inc.

Effective: 2025-06-18
Filed: April 28, 2025, 7:59 PM ET

On April 23, 2025, Carl L. Gordon, Ph.D., CFA notified the board of directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) of his decision not to stand for re-election to the Board at the end of his current term at the Company’s 2025 annual meeting of stockholders currently expected to be held on June 18, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Merdad Parsey was appointed as Director at ArriVent BioPharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board approved, effective April 28, 2025, an increase in the size of the Board from seven (7) directors to eight (8) directors and appointed Merdad Parsey, M.D., Ph.D. to fill the newly created vacancy on the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl L. Gordon departed as Director at ArriVent BioPharma, Inc..

Action: not standing for re-election
Role: Director

Exact text from the filing

On April 23, 2025, Carl L. Gordon, Ph.D., CFA notified the board of directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) of his decision not to stand for re-election to the Board at the end of his current term at the Company’s 2025 annual meeting of stockholders currently expected to be held on June 18, 2025

View on SEC.gov

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-039799

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.